N-adamantan-2-yl-ethane-1,2-diamine | 578713-60-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-adamantan-2-yl-ethane-1,2-diamine
• 英文别名: N'-adamantylethylenediamine；N1-(adamantan-2-yl)ethane-1,2-diamine；N'-(2-adamantyl)ethane-1,2-diamine
• CAS: 578713-60-7
• 化学式: C₁₂H₂₂N₂
• 分子量: 194.32
• InChiKey: LSZAYCTUPPKNOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-adamantan-2-yl-ethane-1,2-diamine 在 盐酸 、 potassium carbonate 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 生成 3,7-dimethyloct-2,6-dienoic acid [2-(adamantan-2-yl-amino)ethyl]amide hydrochloride
  参考文献：
  名称：

  EP3904330

  摘要：

  公开号：
• 作为产物：
  描述：

  金刚烷酮 、 乙二胺 在 对甲苯磺酸 、 sodium tetrahydroborate 作用下， 以 甲苯 、 甲醇 为溶剂， 反应 12.0h， 以81.4%的产率得到N-adamantan-2-yl-ethane-1,2-diamine
  参考文献：
  名称：

  [EN] MMPL3 INHIBITORS, COMPOSITIONS AND USES THEREOF
  [FR] INHIBITEURS DE MMPL3, COMPOSITIONS ET UTILISATIONS ASSOCIÉES

  摘要：

  揭示了抑制结核分枝杆菌膜蛋白MmpL3的抑制剂，包含这些抑制剂的组合物，以及其制备和使用方法。

  公开号：

  WO2020103856A1

文献信息

• ETHYLENEDIAMINE COMPOUND AND USE THEREOF
  申请人：Academy Of Military Medical Sciences

  公开号：EP3904330A1

  公开（公告）日：2021-11-03

  The present invention relates to the field of medicinal chemistry, and relates to an ethylenediamine compound represented by Formula A, pharmaceutically acceptable salts, stereoisomers, tautomers or isomer mixtures, hydrates thereof, solvates thereof, or prodrugs thereof, and use thereof in the treatment of tuberculosis.

  本发明涉及药物化学领域，涉及一种由式 A 代表的乙二胺化合物、药学上可接受的盐、立体异构体、同分异构体或异构体混合物、其水合物、其溶物或其原药，以及其在治疗结核病中的用途。
• [EN] ETHYLENEDIAMINE COMPOUND AND USE THEREOF<br/>[FR] COMPOSÉ D'ÉTHYLÈNEDIAMINE ET SON UTILISATION<br/>[ZH] 乙二胺类化合物及其用途
  申请人：ACAD OF MILITARY MEDICAL SCIENCES

  公开号：WO2020135569A1

  公开（公告）日：2020-07-02

  本发明属于药物化学领域，涉及式A所示的乙二胺化合物，其可药用盐、立体异构体、互变异构体或异构体混合物、其水合物、其溶剂合物或其前体药，及其用于治疗结核病的用途。（A）
• Novel lead generation of an anti-tuberculosis agent active against non-replicating mycobacteria: exploring hybridization of pyrazinamide with multiple fragments
  作者：Shankar D. Markad、Parvinder Kaur、B. K. Kishore Reddy、Murugan Chinnapattu、Anandkumar Raichurkar、Radha Nandishaiah、Manoranjan Panda、Pravin S. Iyer

  DOI：10.1007/s00044-015-1352-6

  日期：2015.7

  The key to shortening tuberculosis (TB) drug regimen lies in eliminating the reservoir of non-replicating persistent (NRP) Mycobacterium tuberculosis (Mtb). Pyrazinamide (PZA) is the only known drug used as part of a combination therapy that is believed to kill NRP Mtb and achieve sterilization. PZA is active only under low pH screening conditions. Screening and identification of NRP-active anti-TB compounds are severely limited because compounds are usually inactive under regular assay conditions. In an effort to design novel NRP-active anti-TB compounds, we used pyrazinamide as a core and hybridized it with the fragments derived from marketed drugs. One of these designs, compound 8, was a hybrid with fluoroquinolone. This compound exhibited > 10 fold improvement in NRP activity under low pH condition as compared to pyrazinamide and a modest activity (0.8 log(10) kill) under nutritionally starved NRP condition. Furthermore, compound 8 was active against fluoroquinolone-resistant strains and did not show any activity in a DNA supercoiling assay (gyrase inhibition), suggesting that its mechanism of action is not that of the parent fluoroquinolone. These results provide a novel avenue in the exploration of new chemotypes that are active against non-replicating Mtb.
• Compositions and methods for the treatment of infectious diseases
  申请人：PROTOPOPOVA Marina Nikolaevna

  公开号：US20110118307A1

  公开（公告）日：2011-05-19

  Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.
• MMPL3 INHIBITORS, COMPOSITIONS AND USES THEREOF
  申请人：SHANGHAITECH UNIVERSITY

  公开号：US20220017492A1

  公开（公告）日：2022-01-20

  The present disclosure relates generally to inhibitors of mycobacterial membrane protein MmpL3, compositions comprising the inhibitors, and methods of preparation and use thereof.